<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412019000500288</article-id>
<article-id pub-id-type="doi">10.24245/gom.v87i5.2601</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación del efecto de la prasterona en el tratamiento del deseo sexual hipoactivo en mujeres posmenopáusicas]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation of the effect of the Prasterone in the treatment of hypoactive sexual desire in postmenopausal women]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Marín]]></surname>
<given-names><![CDATA[Imelda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villavicencio-Delgado]]></surname>
<given-names><![CDATA[Alan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velázquez-Piña]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Juárez de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Juárez de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Juárez de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<volume>87</volume>
<numero>5</numero>
<fpage>288</fpage>
<lpage>294</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412019000500288&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412019000500288&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412019000500288&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Determinar los efectos de la dosis oral diaria de 50 mg de dehidroepiandrosterona en la función sexual de pacientes posmenopáusicas.  MATERIALES Y MÉTODOS:  Estudio experimental, clínico, prospectivo y longitudinal efectuado en pacientes posmenopáusicas atendidas en el Hospital Juárez de México entre los meses de abril a julio de 2017. La muestra se seleccionó de pacientes posmenopáusicas atendidas por primera vez que cumplieran los criterios de inclusión. Administración de 50 mg de prasterona (Biolaif&#8482;) por vía oral cada 24 horas durante 12 meses a las pacientes con protocolo de estudio completo; consulta de seguimiento cada 3 meses. Estadística descriptiva y análisis bidimensional de Friedman. Los estudios estadísticos se realizaron con el programa SPSS versión 22.  RESULTADOS: En 29 pacientes se evaluó el índice de función sexual que se incrementó, posterior al tratamiento oral con 50 mg diarios de prasterona, de una media de 10.8 a 28.1, y a 12 meses en 18 pacientes de una media de 10.6 a 29.1.  CONCLUSIONES: La disfunción sexual es un problema de salud infradiagnosticado en pacientes posmenopáusicas. La administración oral de prasterona (dehidroepiandrosterona) a dosis de 50 mg al día mejoró todos los dominios del índice de función sexual femenina de todas las pacientes estudiadas con resultados estadísticamente significativos, sin efectos secundarios de hiperandrogenismo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: To determine the effects of the administration of 50 mg of DHEA orally daily on sexual function of menopausal patients.  MATERIALS AND METHODS:  We performed an experimental, clinical, prospective and longitudinal study in menopausal patients. We selected the sample from april to july 2017 with menopausal patients who attended for the first time at the clinic who met the inclusion criteria, having a final sample of 29 patients. Patients with a complete study protocol who met the entry criteria were administered 50 mg of prasterone (Biolaif&#8482;) orally daily for 12 months, with a follow-up consultation every 3 months. Descriptive statistics were used for the statistical analysis. Also, Friedman&#8217;s two-dimensional analysis was used. All statistical studies were conducted in the SPSS program, v.22.  RESULTS: Sexual Function Index evaluated with 29 patients at 6 months increased from an average of 10.8 to 28.1. At 12 months with 18 patients, after the treatment with 50 mg prasterone orally daily, it increased from an average of 10.6 to 29.1.  CONCLUSIONS: Sexual dysfunction is an underdiagnosed health problem in patients over the postmenopausal stage. Administration of prasterone (DHEA) at a dose of 50 mg orally daily improved the domains of Female Sexual Function Index of all our patients with statistically significant results, without side effects of hyperandrogenism.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Dehidroepiandrosterona]]></kwd>
<kwd lng="es"><![CDATA[posmenopausia]]></kwd>
<kwd lng="es"><![CDATA[disfunción sexual]]></kwd>
<kwd lng="es"><![CDATA[psicológica]]></kwd>
<kwd lng="es"><![CDATA[hiperandrogenismo]]></kwd>
<kwd lng="es"><![CDATA[enfermedades ováricas]]></kwd>
<kwd lng="en"><![CDATA[Dehydroepiandrosterone]]></kwd>
<kwd lng="en"><![CDATA[Postmenopause]]></kwd>
<kwd lng="en"><![CDATA[Sexual dysfunction, Physiological]]></kwd>
<kwd lng="en"><![CDATA[Hyperandrogenism]]></kwd>
<kwd lng="en"><![CDATA[Ovarian diseases]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of female sexual dysfunction]]></article-title>
<source><![CDATA[Maturitas]]></source>
<year>2009</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>119-23</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labrie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology]]></article-title>
<source><![CDATA[Frontiers in Neuroendocrinology]]></source>
<year>2001</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>185-212</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arlt]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>1998</year>
<volume>83</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1928-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouchard]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in posmenopausal women]]></article-title>
<source><![CDATA[Menopause]]></source>
<year>2009</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>923-31</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DHEA replacement for posmenopausal women]]></article-title>
<source><![CDATA[JCEM]]></source>
<year>2011</year>
<volume>96</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1642-53</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elraiyah]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The benefits and harms of systemic DHEA in posmenopausal women with normal adrenal function: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[JCEM]]></source>
<year>2014</year>
<volume>99</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3536-42</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheffers]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dehydroepiandrosterone for women in the peri or posmenopausal phase]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function]]></article-title>
<source><![CDATA[J Sex Marital Ther]]></source>
<year>2000</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-208</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sioba n]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging]]></article-title>
<source><![CDATA[Menopause]]></source>
<year>2012</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>387-95</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
